Lilly Executive and Leadership Team

William Torres, the Chief Financial Officer & Finance Administrative Manager at Lilly, directs the global financial strategy and administrative operations of the firm. Torres manages capital allocation, budgeting, and financial reporting to ensure the long-term fiscal health of the biopharmaceutical enterprise. By overseeing the financial administrative functions, the Chief Financial Officer & Finance Administrative Manager supports the funding of research-driven innovation in diabetes and oncology. This role involves rigorous oversight of corporate expenditures and investment in manufacturing capabilities to maintain a competitive edge. William Torres collaborates with the executive leadership team to align financial goals with the company's mission of delivering life-saving medicines. Through disciplined fiscal management and strategic planning, the Chief Financial Officer & Finance Administrative Manager secures the resources necessary for global expansion and the continued development of a robust pipeline of prescription therapies.

Miyuki Ashida, the Director, Research & Development & Chief Operating Officer, Project Management at Lilly, directs the integration of scientific discovery with operational execution. Ashida manages complex research pipelines, ensuring that drug development cycles align with rigorous safety standards and corporate timelines. By overseeing cross-functional project teams, the Director, Research & Development & Chief Operating Officer, Project Management optimizes resource allocation across the global biopharmaceutical portfolio. This leadership role requires constant collaboration with clinical researchers to accelerate the transition from laboratory findings to patient-ready therapies. Miyuki Ashida maintains a focus on operational efficiency, driving the development of new medicines in immunology and neuroscience. Through meticulous project oversight, the Director, Research & Development & Chief Operating Officer, Project Management supports the broader mission of delivering life-changing treatments to international markets while maintaining high standards of manufacturing excellence and scientific integrity.

Tobias Gustavsson, the Chief Operating Officer, & Zealand (Australia) at Lilly, manages regional operations and commercial strategy across the Oceania market. Gustavsson directs the distribution and market access initiatives for prescription medicines, ensuring that patients in the region receive timely access to critical therapies. By coordinating with local regulatory bodies and healthcare providers, the Chief Operating Officer, & Zealand (Australia) strengthens the company's footprint in international markets. This role involves scaling operational infrastructure to support the launch of new oncology and diabetes treatments. Tobias Gustavsson monitors regional performance metrics to ensure alignment with global corporate objectives. Through strategic planning and local market engagement, the Chief Operating Officer, & Zealand (Australia) drives sustainable growth and operational excellence, reinforcing the commitment to providing high-quality pharmaceutical solutions to diverse patient populations throughout the Australian and Zealand territories.

Stephanie Brennan, the Global Chief Operating Officer, Medical Affairs, Immunology Heor at Lilly, architects the operational framework for medical evidence generation and immunology research. Brennan oversees the integration of health economics and outcomes research into the global commercialization strategy. By directing the medical affairs teams, the Global Chief Operating Officer, Medical Affairs, Immunology Heor ensures that clinical data effectively communicates the value of new therapies to healthcare systems. This leadership position requires close coordination with global research units to validate the efficacy of immunology treatments. Stephanie Brennan drives the implementation of data-driven strategies that support patient access and therapeutic adoption. Through the management of complex medical evidence portfolios, the Global Chief Operating Officer, Medical Affairs, Immunology Heor enhances the company's market position, ensuring that scientific advancements translate into measurable improvements in patient health outcomes across international healthcare landscapes.

Scott Booziotis, the Executive Director - Early Phase Oncology Medical Affairs, Chief Operating Officer at Lilly, directs the medical strategy for early-stage oncology research and operational execution. Booziotis oversees the transition of experimental cancer therapies from initial clinical trials to broader development phases. By managing the medical affairs team, the Executive Director - Early Phase Oncology Medical Affairs, Chief Operating Officer ensures that clinical data supports the therapeutic potential of new oncology medicines. This role requires constant interaction with research scientists and clinical investigators to refine development protocols. Scott Booziotis drives the operational efficiency of early-phase trials, ensuring that resources focus on the most promising drug candidates. Through strategic leadership in oncology, the Executive Director - Early Phase Oncology Medical Affairs, Chief Operating Officer contributes to the company's mission of transforming cancer care and delivering innovative treatments to patients in need.

Julie Deranick, the Chief Operating Officer, Portfolio & Project Management at Lilly, directs the operational oversight of the entire drug development portfolio. Deranick manages the project management office, ensuring that all research and development programs adhere to strict timelines and quality standards. By coordinating across various therapeutic areas, the Chief Operating Officer, Portfolio & Project Management optimizes the allocation of resources to maximize the impact of the company's R&D investments. This role involves identifying operational bottlenecks and implementing solutions to accelerate the development of new prescription medicines. Julie Deranick collaborates with senior leadership to align portfolio priorities with the company's long-term strategic goals. Through the management of complex project portfolios, the Chief Operating Officer, Portfolio & Project Management ensures that the firm remains at the forefront of biopharmaceutical innovation, delivering essential therapies to patients worldwide.

Jonee Drake, the Director, Clinical Development Chief of Staff and LRL IDS Portfolio Operations and at Lilly, manages the operational flow of clinical trial portfolios and research development initiatives. Drake directs the coordination between clinical development teams and portfolio operations to ensure that drug candidates move efficiently through the development pipeline. By overseeing the administrative and operational functions of the research labs, the Director, Clinical Development Chief of Staff and LRL IDS Portfolio Operations and facilitates the rapid advancement of neuroscience and immunology projects. This role involves streamlining internal processes to enhance productivity and data integrity. Jonee Drake maintains alignment between clinical milestones and corporate strategic goals. Through the management of complex portfolio operations, the Director, Clinical Development Chief of Staff and LRL IDS Portfolio Operations and supports the company's commitment to scientific innovation and the delivery of high-quality pharmaceutical products to patients worldwide.

Robert Petersen, the Chief Revenue Officer, Lilly & Executive at Lilly, directs the global revenue generation strategy and commercial performance. Petersen oversees the sales and marketing operations for the entire portfolio of prescription medicines, ensuring that products reach target markets effectively. By managing commercial teams, the Chief Revenue Officer, Lilly & Executive drives market penetration and revenue growth across diabetes, oncology, and immunology sectors. This role involves analyzing market trends and competitive dynamics to optimize pricing and distribution strategies. Robert Petersen collaborates with the executive team to align commercial efforts with the company's long-term growth objectives. Through the implementation of data-driven sales initiatives, the Chief Revenue Officer, Lilly & Executive ensures that the firm maintains a strong market position and continues to provide essential healthcare solutions to patients on a global scale.

Kushal Vanga, the Director - Chief of Staff (LRL Bengaluru) at Lilly, directs the operational and administrative functions of the research facility in Bengaluru. Vanga oversees the integration of local research activities with the global R&D strategy, ensuring that the facility contributes effectively to the discovery and development of new medicines. By managing the daily operations and strategic priorities of the site, the Director - Chief of Staff (LRL Bengaluru) facilitates collaboration between local scientists and international teams. This role involves optimizing research workflows and resource management to support the company's innovation goals. Kushal Vanga maintains a focus on operational excellence and scientific productivity. Through the leadership of the Bengaluru research hub, the Director - Chief of Staff (LRL Bengaluru) supports the broader mission of advancing pharmaceutical research and delivering high-quality treatments to patients across diverse global markets.

Roberto Servi, the Global Senior VP, Marketing & Chief Marketing Officer, Neuroscience Business Unit at Lilly, directs the global marketing strategy for the neuroscience portfolio. Servi oversees the brand positioning and commercialization efforts for therapies targeting neurological conditions. By managing marketing teams, the Global Senior VP, Marketing & Chief Marketing Officer, Neuroscience Business Unit ensures that the value of neuroscience innovations is effectively communicated to healthcare providers and patients. This role involves developing comprehensive launch strategies and market access plans to drive the adoption of new treatments. Roberto Servi collaborates with research and clinical teams to align marketing messages with scientific evidence. Through strategic brand management and market engagement, the Global Senior VP, Marketing & Chief Marketing Officer, Neuroscience Business Unit supports the company's mission to improve the lives of patients suffering from complex neurological disorders through research-driven innovation.